Knowledge of the clinical cardiologist on high-risk type 2 DM.
What do we know and how can we improve?
What did Adelphi Targis provide?
Our client’s product pipeline contained an injectable GLP-1 analogue and they wanted to explore the therapeutic approach to DM2 in depth before launching the first orally-administered GLP-1 analogue.
Adelphi Targis, in coordination with the SEC (Sociedad Española de Cardiología [Spanish Cardiology Society]) and 4 national opinion leaders, conducted a study based on the self-audit methodology to gauge clinical cardiologist’ knowledge of the diagnosis and treatment of DM2 in patients with ischaemic heart disease or high/very high risk of cardiovascular disease in order to further knowledge of the diagnosis and treatment of patients with DM2, increase healthcare quality and highlight the importance of cardioprotection in these patients.